📘Overview
Updated June 25, 2026Drug discovery is the long, costly search for new medicines — finding a biological target, designing a molecule that acts on it, and validating safety and efficacy. Historically it takes well over a decade and billions of dollars to bring one drug to market, and most candidates fail along the way. The bottlenecks are scientific search problems at enormous scale, which is exactly where AI has made its most celebrated scientific contributions.
💡The AI Opportunity
The landmark was protein-structure prediction: AlphaFold solved a problem that had stumped biology for fifty years, predicting the three-dimensional shape of essentially every known protein. That unlocked a wave of AI-driven discovery — generative models that design candidate molecules, platforms that run millions of virtual experiments, and lab-in-the-loop systems that learn from each round of testing. Work that took years of trial and error is increasingly done in software first, with only the most promising candidates moving to the bench.
🤖AI in Action
AlphaFold predicts protein structures and, through DeepMind's drug spin-off Isomorphic Labs, now drives end-to-end drug design. Recursion Pharmaceuticals and Insilico Medicine run industrial-scale AI discovery platforms with candidates already in clinical trials, while Schrödinger brings physics-based simulation to molecular design. BenevolentAI mines biomedical literature for new targets, and Calico and Manas AI apply machine learning to longevity and oncology discovery. Together they span target finding, molecule design, and trial prediction.
📊Impact on Jobs
AI is compressing the discovery phase of drug development from years toward months and raising the odds that a candidate survives to the clinic, which over time could lower the staggering cost of new medicines. The work shifts from manual screening toward designing and interpreting AI-driven experiments, raising the premium on scientists who can pair deep biology with computational fluency. The honest caveat is that discovery is only the front end — clinical trials still take years and most drugs still fail in human testing, so AI has accelerated the lab, not yet the clinic. But the first AI-designed drugs are now in trials, and that pipeline is the field's most-watched proof point.
Keep track of the topics you follow
- Save the topics you follow
- Get ⚡ alerts when their tools and companies change
- Curated tools for this topic, from 900+ AI tool profiles
- Today’s top AI Stories — the day’s most important AI news, free
Swipe for Recommended for you and My AI Tools
Your AI Hub — sample data. See desktop view example
🛠️Top AI Tools for This Topic
Evo 2Open genome language model from the Arc Institute that reads and writes DNA at single-nucleotide resolution across contexts up to a million base pairs. In August 2026 it became the first AI system shown to design complete, working genomes. Apache 2.0 weights at 1, 7, 20, and 40 billion parameters.
IsoDDE (AlphaFold 4)AI-powered drug design engine building on AlphaFold breakthroughs. Predicts protein-drug binding, metabolism, and side effects to accelerate pharmaceutical R&D. Partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Drug discovery platform combining knowledge graphs and machine learning to identify novel drug targets and repurposing opportunities.
Calico Drug Discovery PlatformAI-powered drug discovery platform applying machine learning to aging biology, protein interactions, and therapeutic target identification. Five clinical-stage candidates plus ~20 preclinical programs.
Manas AI Drug DiscoveryAI-driven drug discovery platform co-founded by Reid Hoffman and Siddhartha Mukherjee. Uses machine learning to identify drug candidates, predict molecular interactions, and optimize therapeutics.
CradleAI protein-engineering software to design better proteins in the browser — used by several top-25 pharma companies to tighten the design-build-test loop.
Chai DiscoveryAI structural-biology models — Chai-1 structure prediction plus Chai-2 and Chai-3 de-novo antibody design — licensed in 2026 by Eli Lilly, Pfizer, Novartis, argenx and Bristol Myers Squibb.
Latent LabsGenerative de-novo protein design from a former AlphaFold lead — including LatentX, a free web app to design proteins in the browser, plus an agentic design assistant.
ProfluentAI protein language models that design new proteins and gene editors — the team behind OpenCRISPR-1, an open-sourced, AI-designed CRISPR gene editor.
Xaira TherapeuticsAI-native drug-discovery platform spanning predictive and generative AI across discovery and development; launched in 2024 with roughly 1 billion dollars, platform-first.
Generate BiomedicinesGenerative-biology platform using AI to design protein therapeutics across modalities; newly public, with a lead anti-TSLP antibody in global Phase 3 for asthma.
Genesis TherapeuticsGEMS AI platform designing small molecules for hard-to-drug targets — partnered with Eli Lilly, Genentech, Gilead, and Incyte.
Iambic TherapeuticsClinical-stage AI drug discovery for oncology — lead HER2-inhibitor candidate in Phase 1, plus a Takeda platform partnership.
Enveda BiosciencesAI drug discovery mining nature's chemistry — machine learning on mass-spectrometry data to find medicines from natural compounds; lead program in Phase 1.
AlphaGenomeGoogle DeepMind's variant-effect model, predicting how a single-letter change to human DNA affects gene regulation. Its Atlas release scores all nine billion possible single-nucleotide variants as a one-petabyte dataset, free for non-commercial research with commercial access via Google Cloud.
Terray TherapeuticsAI drug-discovery platform pairing a proprietary ultra-dense microarray and automated lab with chemistry models including COATI and TerraBind. Runs discovery collaborations with Gilead, Bristol Myers Squibb and Calico.
Owkin K ProOwkin's AI agent for drug research: ask a biology question in plain language and it analyzes patient data to answer. A free tier covers public datasets; the licensed tier adds Owkin's proprietary oncology data.
BoltzBiomolecular AI for drug discovery: open-source Boltz-1, Boltz-2 and BoltzGen models (MIT, weights included) plus the hosted Boltz Lab and API with proprietary BoltzMol-1 and BoltzProt-1 pipelines, a free monthly allowance and usage pricing.
SandboxAQ Large Quantitative ModelsSimulation-grade physics and chemistry models (quantum chemistry, molecular dynamics, microkinetics) exposed through Claude as a conversational interface for drug discovery and materials science. Spun out of Alphabet in 2022; led by CEO Jack Hidary. Claude integration shipped May 2026.